Literature DB >> 2984625

Current results of proton beam irradiation of uveal melanomas.

E S Gragoudas, J Seddon, M Goitein, L Verhey, J Munzenrider, M Urie, H D Suit, P Blitzer, A Koehler.   

Abstract

Proton beam irradiation has been used for the treatment of 241 uveal melanomas over the past 7 1/2 years. Twelve melanomas (5%) were small, 99 (41%) medium, 103 (43%) large and 27 (1%) extra-large melanomas. The mean length of follow-up was 21 months and the median 15 months. Ninety-four percent of the treated lesions with a follow-up more than two years and 65% of tumors with shorter follow-up showed regression. The most recent visual acuity was 20/40 or better in 47% and 20/100 or better in 66%. Ten eyes were enucleated because of complications (9) or continued tumor growth (1). Thirteen patients developed metastases from 4 to 50 months of treatment. Our data indicate that proton irradiation can be used to treat melanomas of various sizes and in a variety of locations, and preliminary results suggest that proton therapy has no deleterious effect on the likelihood of the development of metastases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984625     DOI: 10.1016/s0161-6420(85)34058-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Experimental study on the fractionation schedule for proton irradiation of uveal melanoma.

Authors:  G Wollensak; L Zografos; C Perret; E Egger; H Fritz-Niggli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Intensity modulated proton therapy.

Authors:  H M Kooy; C Grassberger
Journal:  Br J Radiol       Date:  2015-05-27       Impact factor: 3.039

4.  Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications.

Authors:  Klaus-Martin Kreusel; Nikolaos Bechrakis; Juliane Riese; Lothar Krause; Joachim Wachtlin; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

5.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

6.  Intraocular inflammation after proton beam irradiation for uveal melanoma.

Authors:  L Lumbroso; L Desjardins; C Levy; C Plancher; E Frau; F D'Hermies; P Schlienger; H Mammar; S Delacroix; C Nauraye; R Ferrand; C Desblancs; A Mazal; B Asselain
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

Review 7.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

8.  Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival.

Authors:  P De Potter; C L Shields; J A Shields; J R Cater; D J Tardio
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

9.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002

10.  Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma.

Authors:  E Messmer; N Bornfeld; M Foerster; H Schilling; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.